STOCK TITAN

Pamela Esposito to sell 2,500 KYMR shares (NASDAQ: KYMR) after option exercise

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

KYMR: Pamela Esposito filed a Form 144 proposing the sale of 2,500 common shares related to an exercise of stock options for cash, with the transaction dated 02/20/2026. The filing lists prior sales in the past three months: 5,500 shares on 01/20/2026 for $373,521.20 and 27,563 shares on 12/17/2025 for $2,264,479.00.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did the Form 144 for KYMR disclose?

The Form 144 discloses a proposed sale of 2,500 shares tied to an exercise of stock options dated 02/20/2026. It also records two prior sales of 5,500 and 27,563 shares in the three months before the filing.

Who is the reporting person on the KYMR Form 144?

The reporting person is Pamela Esposito, with address listed as 500 North Beacon Street, 4th Floor, Watertown, MA. The broker/dealer shown is Morgan Stanley Smith Barney LLC, Executive Financial Services at 1 New York Plaza, New York.

How much cash was reported from recent insider sales for KYMR?

Recent proceeds reported: $373,521.20 and $2,264,479.00 from sales on 01/20/2026 and 12/17/2025, respectively. The proposed sale on 02/20/2026 is tied to option exercise for cash.

What method is used for the proposed KYMR sale?

The proposed sale arises from an exercise of stock options and is to be settled in cash, dated 02/20/2026. The filing lists prior 10b5-1 sales as separate transactions in the prior three months.

Does the Form 144 show an active 10b5-1 plan for KYMR insider?

Yes, the filing references 10b5-1 sales for Pamela Esposito, with recorded executions on 01/20/2026 (5,500 shares) and 12/17/2025 (27,563 shares), consistent with planned sales under such arrangements.
Kymera Therapeutics, Inc.

NASDAQ:KYMR

KYMR Rankings

KYMR Latest News

KYMR Latest SEC Filings

KYMR Stock Data

6.92B
76.69M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
WATERTOWN